Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Boubia B, Poupardin O, Barth M, Binet J, Peralba P, Mounier L, Jacquier E, Gauthier E, Lepais V, Chatar M, Ferry S, Thourigny A, Guillier F, Llacer J, Amaudrut J, Dodey P, Lacombe O, Masson P, Montalbetti C, Wettstein G, Luccarini JM, Legendre C, Junien JL, Broqua P.

J Med Chem. 2018 Mar 22;61(6):2246-2265. doi: 10.1021/acs.jmedchem.7b01285. Epub 2018 Feb 27.

PMID:
29446942
2.

The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.

Wettstein G, Luccarini JM, Poekes L, Faye P, Kupkowski F, Adarbes V, Defrêne E, Estivalet C, Gawronski X, Jantzen I, Philippot A, Tessier J, Tuyaa-Boustugue P, Oakley F, Mann DA, Leclercq I, Francque S, Konstantinova I, Broqua P, Junien JL.

Hepatol Commun. 2017 Jun 19;1(6):524-537. doi: 10.1002/hep4.1057. eCollection 2017 Aug.

3.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y.

Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.

PMID:
28801346
4.

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.

Ruzehaji N, Frantz C, Ponsoye M, Avouac J, Pezet S, Guilbert T, Luccarini JM, Broqua P, Junien JL, Allanore Y.

Ann Rheum Dis. 2016 Dec;75(12):2175-2183. doi: 10.1136/annrheumdis-2015-208029. Epub 2016 Mar 9.

5.

Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes.

Rébé C, Filomenko R, Raveneau M, Chevriaux A, Ishibashi M, Lagrost L, Junien JL, Gambert P, Masson D.

PLoS One. 2012;7(11):e48738. doi: 10.1371/journal.pone.0048738. Epub 2012 Nov 21.

6.

Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.

Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R, Schteingart C, Junien JL, Trojnar J, Rivière PJ.

Eur J Pharmacol. 2008 Mar 31;583(1):62-72. doi: 10.1016/j.ejphar.2008.01.011. Epub 2008 Jan 24.

PMID:
18282565
7.

Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.

Porreca F, Vanderah TW, Guo W, Barth M, Dodey P, Peyrou V, Luccarini JM, Junien JL, Pruneau D.

J Pharmacol Exp Ther. 2006 Jul;318(1):195-205. Epub 2006 Mar 24.

PMID:
16565167
8.

FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.

Vanderah TW, Schteingart CD, Trojnar J, Junien JL, Lai J, Riviere PJ.

J Pharmacol Exp Ther. 2004 Jul;310(1):326-33. Epub 2004 Mar 1.

PMID:
14993260
9.

Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.

Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO.

Biochem J. 2003 Jul 1;373(Pt 1):179-89.

10.

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.

Diabetes. 2002 May;51(5):1461-9.

11.

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.

Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL.

J Pharmacol Exp Ther. 2002 Apr;301(1):95-102.

PMID:
11907162
12.

Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach.

de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Gonçalves R, Dutrillaux AM, Némati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF.

Am J Pathol. 2001 Aug;159(2):753-64.

13.

Analgesic and antiinflammatory effects of two novel kappa-opioid peptides.

Binder W, Machelska H, Mousa S, Schmitt T, Rivière PJ, Junien JL, Stein C, Schäfer M.

Anesthesiology. 2001 Jun;94(6):1034-44.

PMID:
11465595
14.

GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.

Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE.

J Med Chem. 2001 Feb 1;44(3):453-67.

PMID:
11462984
15.

A novel receptor for calcitonin gene-related peptide (CGRP) mediates secretion in the rat colon: implications for secretory function in colitis.

Esfandyari T, Macnaughton WK, Quirion R, St Pierre S, Junien JL, Sharkey KA.

FASEB J. 2000 Jul;14(10):1439-46.

PMID:
10877837
16.

Fedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat.

Bonaz B, Rivière PJ, Sinniger V, Pascaud X, Junien JL, Fournet J, Feuerstein C.

Neurogastroenterol Motil. 2000 Apr;12(2):135-47.

PMID:
10771495
17.

In vitro stimulation of the prepubertal rat gonadotropin-releasing hormone pulse generator by leptin and neuropeptide Y through distinct mechanisms.

Lebrethon MC, Vandersmissen E, Gérard A, Parent AS, Junien JL, Bourguignon JP.

Endocrinology. 2000 Apr;141(4):1464-9.

PMID:
10746651
18.

Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.

Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML.

Endocrinology. 1999 Sep;140(9):4046-55.

PMID:
10465275
19.

Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors.

Langlois A, Diop L, Friese N, Pascaud X, Junien JL, Dahl SG, Rivière PJ.

Eur J Pharmacol. 1997 Apr 18;324(2-3):211-7.

PMID:
9145774
20.

Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors.

Maurice T, Junien JL, Privat A.

Behav Brain Res. 1997 Feb;83(1-2):159-64.

PMID:
9062676
21.

Reversal by kappa-agonists of peritoneal irritation-induced ileus and visceral pain in rats.

Friese N, Chevalier E, Angel F, Pascaud X, Junien JL, Dahl SG, Riviere PJ.

Life Sci. 1997;60(9):625-34.

PMID:
9048965
22.

Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.

Langlois A, Pascaud X, Junien JL, Dahl SG, Rivière PJ.

Eur J Pharmacol. 1996 Dec 27;318(1):141-4.

PMID:
9007525
23.

Nitric oxide modulates neuropeptide Y regulation of ion transport in mouse ileum.

Rao RK, Lopez Y, Riviere PJ, Pascaud X, Junien JL, Porreca F.

J Pharmacol Exp Ther. 1996 Jul;278(1):193-8.

PMID:
8764351
24.

Antinociceptive effects of neuropeptide Y and related peptides in mice.

Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Riviere PJ, Junien JL, Dahl SG.

Brain Res. 1996 Jun 10;724(1):25-32.

PMID:
8816252
26.

Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.

Gué M, Junien JL, Reeve JR Jr, Rivier J, Grandt D, Taché Y.

Br J Pharmacol. 1996 May;118(2):237-42.

27.

The novel sigma ligand JO 1994 protects against ischaemia-induced behavioural changes, cell death and receptor dysfunction in the gerbil.

O'Neill M, Canney M, Earley B, Junien JL, Leonard BE.

Neurochem Int. 1996 Feb;28(2):193-207.

PMID:
8719709
28.
29.

Attenuation of gastrin-induced gastric acid secretion by antisense oligonucleotide to the CCKB/gastrin receptor.

Rao RK, Lopez Y, Lai J, Riviere PJ, Junien JL, Porreca F.

Neuroreport. 1995 Nov 27;6(17):2373-7.

PMID:
8747156
30.

The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia.

O'Neill M, Caldwell M, Earley B, Canney M, O'Halloran A, Kelly J, Leonard BE, Junien JL.

Eur J Pharmacol. 1995 Sep 5;283(1-3):217-25.

PMID:
7498313
31.

In vivo modulation of sigma receptor sites by calcitonin gene-related peptide in the mouse and rat hippocampal formation: radioligand binding and electrophysiological studies.

Bouchard P, Monnet F, Bergeron R, Roman F, Junien JL, de Montigny C, Debonnel G, Quirion R.

Eur J Neurosci. 1995 Sep 1;7(9):1952-62.

PMID:
8528471
32.

Interaction between CCK and opioids in the modulation of the rectocolonic inhibitory reflex in rats.

Gué M, del Rio C, Junien JL, Buéno L.

Am J Physiol. 1995 Aug;269(2 Pt 1):G240-5.

PMID:
7653564
33.
34.

Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors.

Lagente V, Pruniaux MP, Junien JL, Moodley I.

Am J Respir Crit Care Med. 1995 Jun;151(6):1720-4.

PMID:
7539326
35.

Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures.

Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL.

Behav Pharmacol. 1995 Apr;6(3):215-222.

PMID:
11224329
36.

Review article: the hypersensitive gut--peripheral kappa agonists as a new pharmacological approach.

Junien JL, Riviere P.

Aliment Pharmacol Ther. 1995 Apr;9(2):117-26. Review.

PMID:
7605851
37.
38.

Central nervous system pharmacology of neuropeptide Y.

Wettstein JG, Earley B, Junien JL.

Pharmacol Ther. 1995 Mar;65(3):397-414. Review.

PMID:
7644568
39.

Effect of fedotozine on the cardiovascular pain reflex induced by distension of the irritated colon in the anesthetized rat.

Langlois A, Diop L, Rivière PJ, Pascaud X, Junien JL.

Eur J Pharmacol. 1994 Dec 27;271(2-3):245-51.

PMID:
7705424
40.
41.
42.
43.

Cholecystokinin blockade of emotional stress- and CRF-induced colonic motor alterations in rats: role of the amygdala.

Gué M, Tekamp A, Tabis N, Junien JL, Buéno L.

Brain Res. 1994 Sep 26;658(1-2):232-8.

PMID:
7834346
44.

Fedotozine reversal of peritoneal-irritation-induced ileus in rats: possible peripheral action on sensory afferents.

Riviere PJ, Pascaud X, Chevalier E, Junien JL.

J Pharmacol Exp Ther. 1994 Sep;270(3):846-50.

PMID:
7932195
45.

A C-fiber reflex modulated by heterotopic noxious somatic stimuli in the rat.

Falinower S, Willer JC, Junien JL, Le Bars D.

J Neurophysiol. 1994 Jul;72(1):194-213.

PMID:
7965005
46.

Interleukin 1 induces a neurally mediated colonic secretion in rats: involvement of mast cells and prostaglandins.

Theodorou V, Eutamene H, Fioramonti J, Junien JL, Bueno L.

Gastroenterology. 1994 Jun;106(6):1493-500.

PMID:
8194694
47.
48.

Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats.

Diop L, Rivière PJ, Pascaud X, Dassaud M, Junien JL.

Eur J Pharmacol. 1994 May 12;257(1-2):181-7.

PMID:
8082700
49.

Tonic regulation of mouse ileal ion transport by nitric oxide.

Rao RK, Riviere PJ, Pascaud X, Junien JL, Porreca F.

J Pharmacol Exp Ther. 1994 May;269(2):626-31.

PMID:
7514221
50.

Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung.

Lagente V, Moodley I, Perrin S, Mottin G, Junien JL.

Eur J Pharmacol. 1994 Apr 1;255(1-3):253-6.

PMID:
8026552

Supplemental Content

Loading ...
Support Center